<DOC>
	<DOC>NCT01320033</DOC>
	<brief_summary>The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory lesion counts.</brief_summary>
	<brief_title>Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris</brief_title>
	<detailed_description>Investigator's global assessment and lesion count will be performed at each study visit.</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Male and female subjects 12 years of age or older acne vulgaris with facial involvement A score of 3 (Moderate) or 4 (Severe) on the Investigator's Global Assessment Scale (inflammatory) 25 to 75 inflammatory lesions (papules and pustules) on the face (including the nose) More than two acne nodules/cysts on the face Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne, etc.), or severe acne requiring systemic retinoid treatment Underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea Beard or facial hair which might interfere with study assessments planning excessive exposure to sun or ultraviolet light during the study (i.e. natural or artificial sunlight, including tanning booths and sun lamp) Use of oral contraceptives solely for control of acne Liver function test ALT and/or AST 2.5 times above upper limit of normal Renal function test serum creatinine at 150 umol/L (17 mg/L) or higher Presence of oral or genital candidiasis or history of multiple episodes of oral or genital candidiasis Females who intend to conceive a child within 5 months following Baseline visit Males who intend to conceive a child with partner during the study period Requiring concomitant use of methoxyflurane</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>acne vulgaris</keyword>
	<keyword>inflammatory lesions</keyword>
</DOC>